ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
5 hedge funds and large institutions have $101K invested in ELITE PHARMACEUTICAL in 2015 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
3% more capital invested
Capital invested by funds: $98K → $101K (+$2.8K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCA
Personal Capital Advisors
Redwood City,
California
|
+$6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GA
1
Geneva Advisors
Chicago,
Illinois
| $67K | – | – | – |
|
|
JAFL
2
Jay A. Fishman Ltd
Troy,
Michigan
| $13.8K | – | – | – |
|
|
GIA
3
Guyasuta Investment Advisors
Pittsburgh,
Pennsylvania
| $13K | – | – | – |
|
|
PCA
4
Personal Capital Advisors
Redwood City,
California
| $6K | +$6K | +25,000 | New |
|
|
WRM
5
Westport Resources Management
Westport,
Connecticut
| $1K | – | – | – |
|
|
6
Ameriprise
Minneapolis,
Minnesota
| – | -$15K | -75,000 | Closed |
|
ELI Hedge Fund Activity: Q3 2015 in Review
5 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q3 2015, worth a combined $101K — up 2.9% from $98K a quarter earlier.
Fund positioning in ELI was balanced in Q3 2015: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Personal Capital Advisors, opening a new position worth an estimated $6K. The largest seller was Ameriprise, exiting entirely with an estimated $15K sold.
- 5 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $101K of ELITE PHARMACEUTICAL stock for Q3 2015, up 2.9% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q3 2015 and 1 closed out, a net change of 0 holders.
- The largest ELITE PHARMACEUTICAL buyer in Q3 2015 was Personal Capital Advisors, an estimated $6K added.
- The largest ELITE PHARMACEUTICAL seller in Q3 2015 was Ameriprise, an estimated $15K sold.
Based on aggregated 13F filings for Q3 2015.